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Key Points  
 Ticagrelor acts as an inverse agonist at the P2Y12 receptor, inhibiting basal agonist-
independent signalling. 
 Ticagrelor inhibits the adenosine transporter ENT1 not only on erythrocytes, but on 
platelets too. 
 
Abstract  
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an 
inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought 
to further characterise its molecular mechanism of action. Initial studies showed that 
ticagrelor promoted a greater inhibition of ADP-induced Ca2+ release in washed platelets 
versus other P2Y12R antagonists. This additional effect of ticagrelor beyond P2Y12R 
antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside 
transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and 
activation of Gs-coupled adenosine A2A receptors. This contributed to an increase in basal 
cAMP and VASP phosphorylation. In addition, ticagrelor increased platelet cAMP and VASP 
phosphorylation in the absence of ADP in an adenosine receptor-independent manner. We 
hypothesised that this increase originated from a direct effect on basal agonist-independent 
P2Y12R signalling, and this was validated in 1321N1 cells stably transfected with human 
P2Y12R. In these cells, ticagrelor blocked the constitutive agonist-independent activity of the 
P2Y12R, limiting basal Gi-coupled signalling and thereby increasing cAMP levels. These data 
suggest that ticagrelor has the pharmacological profile of an inverse agonist. Based on our 
results showing insurmountable inhibition of ADP-induced Ca2+ release and forskolin-
induced cAMP, the mode of antagonism of ticagrelor also appears non-competitive, at least 
functionally. In summary, our studies describe two novel modes of action of ticagrelor, 
inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute to its effective 
inhibition of platelet activation. 
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Introduction  
Acute coronary syndrome (ACS) is amongst the leading causes of death in the world1. 
Platelets play a pivotal role in the pathogenesis of ACS. Following atherosclerotic plaque 
rupture, platelets are exposed to potent agonists, collagen and thrombin, that trigger 
platelet activation and aggregation. Subsequent release of ADP from activated platelets and 
its activation of platelet P2Y12Rs have a central role in amplifying the response to the initial 
stimulus. P2Y12R signalling is therefore well established as a major positive feed-forward 
amplification mechanism to a wide variety of platelet agonists. Pharmacological blockade of 
the P2Y12R represents an important and clinically well validated target for the treatment and 
prevention of thrombosis2,3. 
Unlike the thienopyridine P2Y12R antagonists (ticlopidine, clopidogrel and prasugrel), 
ticagrelor binds to the P2Y12R in a reversible manner
4,5. Also unlike the thienopyridines, 
which are all pro-drugs requiring metabolic activation to exert an antiplatelet effect, 
ticagrelor is direct acting. In addition, its main circulating metabolite, AR-C124910XX 
(present in plasma at 30-40% of parent6), has similar potency at the P2Y12R as ticagrelor
7. In 
comparison to clopidogrel, ticagrelor provides higher and more consistent platelet 
inhibition8,9. Large clinical trials carried out across 43 countries in patients with ACS have 
demonstrated a lower rate of death due to adverse cardiovascular events overall, without 
an increase in serious bleeding in patients treated with ticagrelor  compared to 
clopidogrel10. Ticagrelor is also superior to placebo when given on top of aspirin in patients 
with a prior myocardial infarction11. Intriguingly, ticagrelor has recently been shown to 
inhibit the equilibrative nucleoside transporter 1 (ENT1)12, an adenosine transporter, on red 
blood cells and thereby to increase extracellular adenosine levels in vitro and in the plasma 
of ticagrelor-treated patients13-16. Ticagrelor has also been shown to augment a number of 
physiological responses induced by adenosine, including increased coronary blood flow and 
adenosine-dependent inhibition of platelet aggregation15,17,18. Some adverse effects 
associated with ticagrelor include dyspnoea and ventricular pauses, effects also seen with 
intracoronary administration of exogenous adenosine19,20. 
The aim of this study was to further elucidate the molecular mode of action of ticagrelor on 
platelets beyond its well-established antagonism of the P2Y12R. Using isolated human 
platelets, we tested whether ticagrelor’s inhibition of adenosine transport could contribute 
to changes in downstream signalling. We also verified whether these effects could be 
explained by the inhibition of platelet-expressed ENT1 by ticagrelor. We also tested the 
hypothesis that ticagrelor blocks constitutive agonist-independent P2Y12R activity. The aim 
was to determine whether ticagrelor is an inverse agonist, unlike the active metabolite (R-
138727) of the thienopyridine prasugrel, and thus help us gain a better comprehension of 
ticagrelor’s efficacy. 
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Materials and Methods 
Reagents 
Membrane stripping solution and Fura-2 AM were from Thermo Fisher Scientific 
(Northumberland, UK). NECA, xanthine amine congener (XAC), AR-C 66096 tetrasodium salt, 
PSB 0739, 6-S-[(4-Nitrophenyl)methyl]-6-thioinosine (NBMPR) were procured from Tocris 
Bioscience (Bristol,UK). R-138727 was obtained from Eli Lilly Research Laboratories 
(Indianapolis, Indiana,USA). Ticagrelor was provided by AstraZeneca (Mölndal, Sweden). Cell 
culture reagents included Dulbecco's modified Eagle's medium (DMEM), fetal calf serum 
(FCS), penicillin-streptomycin and G418, which were from Invitrogen (Paisley, UK). 
Commercial antibodies used to detect Phospho-VASP (Ser157), VASP, Phospho-ERK, ERK 
were from New England Biolabs (Hertfordshire, UK), α-tubulin from Sigma Aldrich (Dorset, 
UK), ENT1 from Abcam (Cambridge, UK) and secondary mouse and rabbit horseradish 
peroxidase-conjugated antibodies were from GE Healthcare (Buckinghamshire,UK). All other 
reagents were purchased from Sigma-Aldrich (Dorset,UK). 
 
Preparation of human platelets  
Human blood was collected after informed consent from healthy, drug-free volunteers as 
described previously21. Platelets were rested for at least half an hour in the presence of 
0.02U/ml apyrase and 10µM indomethacin prior to use in the experiments. All platelet 
preparations were conducted at room temperature and platelets were stored at 30°C. 
 
Light transmission aggregometry 
PRP samples stored at 30 °C were pre-heated to 37°C for 2 minutes and stirred at 1000 rpm 
in an aggregometer (Chronolog Model 700, Labmedics, Manchester, UK) before adding ADP 
(10µM). The change in optical density relative to PPP (100% aggregation reference) was 
recorded for 6 minutes and maximum aggregation extent was used for data analysis. 
 
SDS-PAGE and immunoblotting 
Protein samples were boiled in SDS sample buffer and subjected to Western analysis as 
previously described22. Where required, blots were stripped using Restore Western blot 
stripping solution (Thermo Scientific) and re-probed for protein of interest. Quantification 
was performed by densitometry using the ImageJ software (NIH, USA). Mean integrated 
density of bands of interest was used as a quantitative measurement of immunoblot 
intensity, divided by the mean integrated density of total protein (α-tubulin band), then 
normalised to the relevant control levels. 
 
Measurement of cytosolic free Ca2+ in platelets 
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Measurement of intracellular Ca2+ release was adapted from a method used previously22. 
PRP was incubated with 4μM Fura-2 AM (Life Technologies, Paisley, UK) in the presence of 
0.02U/ml apyrase and 10µM indomethacin at 30 ˚C for 1 hour. Platelets were pelleted by 
centrifugation at 550g for 10 minutes and resuspended in a modified Tyrode’s-HEPES buffer 
(containing 0.02U/ml apyrase and 10 µM indomethacin) to a final concentration of 
4×108/ml. Platelets were allowed to rest in the presence of vehicle (0.1% DMSO) or P2Y12R 
antagonist for 30 minutes at 30˚C. ADP (10µM)-induced changes in Ca2+ levels were 
subsequently monitored at 37˚C using a Tecan Infinite M200 PRO microplate reader 
(Labtech International Ltd, East Sussex, UK), with fluorescence excitation set at 340 and 380 
nm, and emission at 510nm. 
 
Measurement of platelet cAMP levels 
Washed platelets were stimulated in the presence of the phosphodiesterase inhibitor IBMX 
(100µM) and drug induced changes in platelet cAMP levels assessed as described before23. 
 
Cell culture 
1321N1 cells stably expressing either haemagglutinin (HA)-tagged P2Y12 or pcNEO vector 
were maintained in DMEM supplemented with 10% FCS, 100 units/ml penicillin-
streptomycin and 400μg/ml G418 (Geneticin) at 37 °C in a humidified atmosphere of 95% air 
and 5% CO2. The cloning and stable expression of P2Y12 tagged at the N-terminus with HA in 
1321N1 cells has previously been described23. 
 
Measurement of P2Y12R activity in 1321N1 cells 
P2Y12R-stimulated inhibition of forskolin-stimulated adenylyl cyclase was measured in 
1321N1 cells as previously described23. Changes in cell VASP-P levels were assessed by 
immunoblotting as described above. Drug-induced changes in cell cAMP levels were 
determined using a cAMP Enzyme Immunoassay Kit according to the manufacturer’s 
instructions. 
 
Statistical analysis 
Graphs were generated using Graphpad Prism (San Diego, CA, USA). Concentration-
response curves were fitted to the data via a variable slope model of non-linear regression. 
Data points are displayed as mean ± standard error. One-way analysis of variance (ANOVA), 
unless otherwise specified, was used to detect statistically significant differences and 
Bonferroni post-hoc analysis was applied. 
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Results 
Ticagrelor-mediated inhibition of platelet Ca2+ release is partly adenosine receptor-
dependent 
Ticagrelor, AR-C 66096 and the active metabolite of prasugrel, R-138727, all inhibited ADP 
(10μM)-induced platelet aggregation in human PRP in a concentration-dependent manner 
(Figure 1A). Ticagrelor (10μM) significantly decreased the peak Ca2+ response to ADP (10μM; 
Figure 1B) with no evident change in the overall shape of the calcium trace versus that seen 
with agonist alone (data not shown). The P2Y12R antagonists AR-C 66096 (10 μM) and R-
138727 (10μM) also inhibited Ca2+ release, although to a lesser extent than ticagrelor, as 
evident by the higher ADP-mediated maximum effect (Emax) values (Table 1).  
Pre-incubation with the adenosine receptor antagonist xanthine amine congener (XAC; 
10μM) partly reversed the peak Ca2+ response in ticagrelor-treated platelets, to levels 
comparable to Ca2+ responses measured in AR-C 66096- and R-138727-treated platelets 
(Figure 1C). XAC (10μM) treatment had no further effect on AR-C 66096- and R-138727-
treated platelets (data not shown). 
 
Ticagrelor induces an adenosine receptor-dependent increase in VASP-P in platelets 
Incubation of washed platelets with ticagrelor induced a time- and concentration-
dependent increase in vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) in 
the absence of platelet agonist (Figure 2A-D). Ticagrelor (10µM) induced a significant 
increase in VASP-P levels by 30 minutes with an upward trend at earlier time points (Figure 
2A-B). Washed platelets incubated for a fixed time period (60 min) with a range of ticagrelor 
concentrations (0.1-10µM) showed significant increases in VASP-P levels above basal, with 
concentrations greater than 3 µM (Figure 2C-D). Unlike ticagrelor (10µM) none of the three 
alternative P2Y12R antagonists, AR-C 66096, PSB 0739 and R-138727 (10µM) were able to 
increase VASP-P beyond basal levels after incubation with platelets for 60 minutes (Figure 
2E-F). 
Similar to ticagrelor, the non-selective adenosine receptor agonist, NECA (1µM;60 min) 
induced an increase in VASP-P (Figure 2G-H). Pre-incubating washed platelets with the 
unselective adenosine receptor antagonist XAC (1µM; 30 min) attenuated, but did not 
completely abolish subsequent ticagrelor (10µM; 60 min)- or NECA- (10µM; 60 min) induced 
increases in VASP-P (Figure 2G-H). The inhibitory effect of XAC was numerically but not 
significantly greater in combination with NECA as compared to ticagrelor. The adenosine 
receptor-dependent increase in VASP-P by ticagrelor was also observed in the presence of 
1mM extracellular Ca2+ (data not shown). Pre-incubation with the A2A adenosine receptor-
selective antagonist SCH 442416 (1µM; 30 min) significantly attenuated (p<0.05; n=6) 
subsequent ticagrelor (10µM; 60 min)-induced increases in VASP-P whereas the A2B 
adenosine receptor selective antagonist PSB 603 (1µM; 30 min) had no effect. VASP-P levels 
(fold over basal) were 9.19 ± 2.98, 0.92 ± 0.37 and 8.54 ± 3.97 for ticagrelor alone, ticagrelor 
+ SCH 442416 and ticagrelor + PSB 603 respectively). 
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Ticagrelor-mediated inhibition of platelet ENT1 likely explain adenosine-related effects 
Incubation of washed platelets with the ENT1-specific inhibitor, NBMPR (1µM), induced a 
time-dependent increase (p<0.01) in VASP-P (Figure 3A-B). This increase was comparable to 
that seen with ticagrelor (10µM). NBMPR in combination with ticagrelor did not significantly 
increase VASP-P compared to ticagrelor or NBMPR alone (Figure 3C-D). Pre-incubation of 
platelets with adenosine deaminase (ADA), which degrades adenosine into inosine, together 
with NBMPR or ticagrelor, prevented both NBMPR- (p<0.01) and ticagrelor-mediated 
(p<0.01) increases in VASP-P. Direct evidence of the presence of ENT1 in human platelets 
was obtained by immunoblotting (Figure 3E) using an ENT1-specific antibody.  
 
Ticagrelor induces an adenosine receptor-independent increase in VASP-P and cAMP in 
platelets 
XAC pre-incubation (10µM) reduced basal VASP-P (Figure 4A and Figure 4C), supporting the 
presence of endogenous adenosine and adenosine receptor signalling in our washed 
platelet preparations. In the presence of XAC, ticagrelor (10µM) produced a time- (Figure 
4A-B) and concentration-dependent (Figure 4C-D) increase in VASP-P. The adenosine 
receptor agonist NECA (1µM; Figure 4E-F) and the P2Y12R antagonists AR-C 66096, PSB 0739 
and R-138727 (all at 10µM) however, did not affect VASP-P levels under the same 
conditions (Figure 4E-F). Ticagrelor was also still able to increase VASP-P in the presence of 
AR-C 66096, PSB 0739 or R-138727 (10μM; Figure 5A-B). 
PGE1 (1μM), a well-established stimulator of cAMP production through activation of platelet 
prostanoid receptors, increased cAMP levels which was attenuated by P2Y12R activation 
with ADP (10μM; Figure 5C). As expected, the P2Y12 antagonists ticagrelor, AR-C 66096 and 
R-138727 (10μM) attenuated the ADP-mediated reduction in cAMP levels (Figure 5C). 
However, only ticagrelor (10μM; 60 min) could modulate basal cAMP levels as evident by a 
2-fold increase in cAMP (p<0.05). Pre-incubation with XAC (10 μM; 30 min) (Figure 5D) 
partially attenuated this ticagrelor-induced increase in cAMP. However, even in the 
presence of XAC, ticagrelor still significantly increased platelet cAMP levels, indicative of an 
adenosine-independent component in addition to the adenosine-dependent effect. 
 
Ticagrelor also induces an adenosine receptor-independent increase in VASP-P in 1321N1 
cells expressing the P2Y12R 
Given that ticagrelor increased basal platelet cAMP and VASP-P levels in the absence of 
adenosine receptor signalling, we hypothesised that ticagrelor was directly modulating 
agonist-independent P2Y12R activity. In order to test this, we used P2 receptor-null 1321N1 
human astrocytoma cells overexpressing the human P2Y12R
24,25. 
Pre-incubation with IBMX (100µM; 15 min), a phosphodiesterase inhibitor preventing 
enzymatic breakdown of cAMP, increased VASP-P as did forskolin (100nM; 5 min), a direct 
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activator of adenylyl cyclase. Forskolin-stimulated increases in VASP-P were, as expected, 
attenuated by P2Y12R stimulation with ADP (10μM; 5 min). Ticagrelor (10μM; 5 min) 
increased VASP-P levels above basal whilst the other P2Y12 antagonists AR-C 66096 and R-
138727 (10μM; 5 mins) produced more modest effects (Figure 6A-B).  
The effect of ticagrelor on the phosphorylation state of extracellular signal-regulated kinase 
(ERK) and Akt/protein kinase B, both shown to be activated downstream of P2Y12R 
activation26,27 was explored. Ticagrelor produced no significant changes in ERK (Figure 6C-D) 
or Akt (data not shown) phosphorylation in P2Y12R expressing cells. 
Ticagrelor had no effect on VASP-P in pcNEO (vehicle vector)-transfected P2Y receptor-null 
cells, supporting a P2Y12-dependent effect. Further, in P2Y12R-expressing cells, pre-
treatment with XAC (1μM; 15 mins) had no effect on ticagrelor-stimulated changes in VASP-
P (Figure 6E-F), supporting an adenosine-independent effect. 
 
Ticagrelor decreases the agonist-independent activity of the P2Y12R 
As expected and previously demonstrated, ADP produced a concentration-dependent 
decrease in forskolin-stimulated adenylyl cyclase activity (Figure 7A-B). Pre-treatment with 
either ticagrelor (Figure 7A) or AR-C 66096 (Figure 7B) both shifted the concentration-
response curve of ADP in a parallel manner. However, the highest concentration of 
ticagrelor (30nM) reduced the maximal effect of the agonist ADP (Figure 7A). Schild-plot 
analysis of the shifts in ADP EC50 produced by increasing concentrations of ticagrelor 
revealed a slope of 1.73±0.12 and a pA2 of 8.79±0.31. Meanwhile at all concentrations of 
AR-C 66096, antagonism was surmountable (Figure 7B). Schild-plot analysis of the respective 
shifts of in ADP EC50 concentrations gave a slope of close to unity (1.01±0.10) and a pA2 of 
8.2±0.22. Our Schild analysis therefore suggests that, ticagrelor and AR-C 66096 are acting 
as non-competitive and competitive antagonists respectively, with pA2 values in broad 
agreement to those reported28. 
Upon closer examination of forskolin-stimulated adenylyl cyclase activity, a significant 
reduction was noted in P2Y12R-expressing cells versus vector control cells (Figure 7D), 
indicating constitutive (agonist-independent) activity of the P2Y12R. This attenuation of 
forskolin responsiveness due to P2Y12R expression was reversed by ticagrelor (10μM; 30 
min) but not with the other P2Y12R antagonists (Figure 7E). The ability of ticagrelor to 
modulate this agonist-independent P2Y12R activity was concentration-dependent (Figure 7F) 
and not affected by XAC pre-incubation (1μM; 15 min; data not shown). In summary, this set 
of results from 1321N1 cells indicated that ticagrelor was able to reduce agonist-
independent P2Y12R activity by acting as an inverse agonist.  
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Discussion 
The P2Y12R plays a central role in platelet activation and thrombosis, and has been by far the 
most successful target for antiplatelet therapy2,10,17,29-31. Ticagrelor is the first non-
thienopyridine P2Y12 antagonist approved for the prevention of thrombotic events in ACS 
patients. Unlike the thienopyridines, ticagrelor is direct-acting and binds to P2Y12 in a 
reversible manner to block platelet activity. Clinical studies provide evidence that ticagrelor 
treatment can offer superior efficacy compared to clopidogrel, with a lower mortality rate 
resulting from vascular causes, myocardial infarction or stroke.. The reasons for this are 
unclear but have recently been reviewed7. This study aimed to fully characterise how 
ticagrelor modulates human platelet function and demonstrates two novel antiplatelet 
mechanisms. Firstly, ticagrelor is able to directly block platelet ENT1 activity, leading to a 
rise in local extracellular adenosine levels, which in turn activates platelet A2A adenosine 
receptors, increasing platelet cAMP levels and reducing platelet activity. Secondly, ticagrelor 
inhibits agonist-independent platelet P2Y12R activity, which indicates that ticagrelor has the 
pharmacological profile of an inverse agonist. These effects are in addition to ticagrelor’s 
primary antiplatelet mechanism of action, P2Y12 antagonism. 
A number of recent studies have shown that ticagrelor can increase extracellular adenosine 
levels15,16. Experiments in whole blood demonstrated that ticagrelor blocked ENT1 
adenosine transporters on red blood cells, resulting in increased plasma adenosine levels 
and inhibition of platelet aggregation15. However, a direct effect on platelet adenosine 
transport has not yet been demonstrated. In order to investigate potential effects on 
platelet signalling, we examined changes in platelet ADP-induced Ca2+ release, basal cAMP 
and basal VASP-P levels. We show that ticagrelor was more effective at reducing ADP-
induced platelet Ca2+ release than other P2Y12 antagonists with an evident decrease in 
agonist-stimulated peak Ca2+ concentrations but no overall change in the shape of the Ca2+ 
trace. The antagonism of the Ca2+ responses by ticagrelor, R-138727 and AR-C 66096 was 
insurmountable. For R-138727, this could be considered as consistent with it being an 
irreversibly-binding antagonist. Ticagrelor32 and the ATP analogue, AR-C 6609633 however, 
reversibly bind to the P2Y12R and yet displayed insurmountable antagonism.  
In addition, ticagrelor treatment, unlike other P2Y12 antagonists produced a time- and 
concentration-dependent increase in basal VASP-P in human washed platelets. Importantly, 
pre-treatment of platelets with the adenosine receptor antagonist XAC attenuated but did 
not abolish the ticagrelor-induced increase in VASP-P. This effect was independent of the 
presence of extracellular Ca2+. Although platelets express the A2A adenosine receptor 
subtype and at lower levels the A2B subtype
34,35, only the A2A adenosine receptor-selective 
antagonist SCH 442416 attenuated the ticagrelor-induced increase in platelet VASP-P.  
Our study is the first to demonstrate that ticagrelor is able to inhibit platelet-expressed 
ENT1. Previously, it has been shown that ticagrelor selectively inhibit cellular adenosine 
uptake via inhibition of ENT1 at clinically relevant concentrations 12 and that this inhibition 
translates into an increase in extracellular adenosine concentration 15,16. ENT1 on red blood 
cells are believed to play a key role because these cells are thought to be the main sink of 
adenosine in the circulation. However, this could not be applicable to our study since our 
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assays were carried out using washed platelets in the absence of erythrocytes. Proteomics 
databases (e.g. Platelet Web36, ProteomicsDB37) suggest that platelets do express ENT1 
whilst our studies used Western blotting to confirm for the first time that platelets express 
ENT1. The identified protein was approximately 50 kDa in size, similar to that observed by 
other groups38,39. Importantly, this band was not found in a mixed culture of rat glial cells 
which are reported to have little or no ENT1 expression40. Further, the ENT1-selective 
inhibitor NBMPR, like ticagrelor, caused a time-dependent increase in VASP-P in washed 
platelets. Likewise, VASP-P peaked after a 60-minute incubation period with NBMPR or 
ticagrelor, indicative of a gradual build-up of adenosine after the adenosine transporter 
ENT1 was blocked. Hence following ticagrelor treatment, it would appear that inhibition of 
platelet as well as red blood cell ENT1 contribute to an increase in extracellular adenosine 
levels in blood. 
Our results prompt us to speculate on the source of adenosine in our studies. Adenosine 
may be generated following ATP or ADP breakdown during preparation of washed platelets, 
which is undertaken in the presence of apyrase to preserve P2Y1R and P2Y12R 
responsiveness 23. It is well established that platelets express CD39/nucleoside triphosphate 
diphosphohydrolase 1 (NTPDase1), an ecto-nucleosidase enzyme that hydrolyses both ADP 
and ATP to AMP 41,42. Another platelet membrane-anchored enzyme, CD73 then converts 
AMP into adenosine 43,44. Critically, addition of adenosine deaminase which degrades 
adenosine into inosine, effectively blocked any adenosine-dependent effects of ticagrelor. 
Therefore as in previous studies, our data supports the fact that that ticagrelor does not 
directly bind to or stimulate platelet adenosine receptors but induces adenosine effects by 
increasing extracellular adenosine levels 12,45. 
Our studies also show for the first time that ticagrelor can affect agonist-independent 
platelet cAMP and VASP-P, likely via P2Y12R. This effect was adenosine receptor-
independent as ticagrelor could still increase levels of platelet cAMP and VASP-P in the 
presence of adenosine receptor antagonism with XAC. The kinetics of the rise in VASP-P 
following XAC-induced adenosine receptor antagonism was notably faster compared to that 
in the absence of XAC. We hypothesise that the slow rise of VASP-P can be attributed to the 
gradual build-up of adenosine. In contrast, the rapid change in VASP-P apparent following 
adenosine receptor antagonism is suggestive of an effect consequent to direct receptor-
ligand interaction. We suggest that ticagrelor is acting as an inverse agonist at the P2Y12R, 
therefore having the opposite effect to ADP. This property again appears unique to 
ticagrelor versus the other P2Y12R antagonists tested (Figure 4G-H). 
Our hypothesis was validated in 1321N1 cells stably expressing the human P2Y12R. 
Ticagrelor increased VASP-P only in 1321N1 cells expressing the P2Y12R and not in P2Y null 
vector controls. In addition, we showed that XAC pre-incubation had no effect on ticagrelor-
induced increase in VASP-P, indirectly supporting a selective effect on the P2Y12R. 
Intriguingly, unlike in platelets, R-138727 but not AR-C 66096 also marginally increased 
VASP-P. Therefore, R-138727 may potentially also effect agonist-independent P2Y12R 
activity. However, as we did not see any measurable effect on VASP-P in human platelets, or 
changes in forskolin responsiveness (see below), we did not explore this further. 
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It is also worth noting that ticagrelor did not affect ERK (Figure 6C-D) or Akt activation (data 
not shown) which are both phosphorylated following P2Y12R activation
46. Closer 
examination of P2Y12R signalling in 1321N1 cells showed that the receptor exhibited a high 
degree of constitutive activity visualised by an attenuation of forskolin responsiveness only 
in P2Y12R-expressing cells
47. Pre-incubation with apyrase to remove residual ADP or pre-
incubation with other P2Y12R antagonists had no effect on forskolin responsiveness, 
providing further evidence that the receptor is able to initiate signalling in the absence of an 
agonist. Only ticagrelor was able to suppress agonist-independent activity of the P2Y12R, as 
indicated by increased forskolin-induced cAMP levels in receptor-expressing cells to a level 
comparable with non-receptor-expressing cells. Our data provides compelling evidence that 
ticagrelor is an inverse agonist, stabilising the receptor in an inactive conformation upon 
binding and preventing agonist-independent coupling to Gi
48,49. We do recognise that these 
studies were undertaken in cell lines overexpressing the P2Y12R (approximately 10 times 
greater than what we find in human platelets50). Although receptor overexpression can 
affect the degree of agonist-independent activity, it is reassuring that we find comparable 
changes in the ability of ticagrelor to modulate basal P2Y12R activity when the receptor is 
endogenously expressed on human platelets. Importantly, the “ionic lock” between the 
bottom of transmembrane domains III and VI seen in some G protein-coupled receptors 
(GPCRs), and which is thought to stabilise the inactive conformation of a GPCR in the 
absence of agonist ligand, is not present in the P2Y12R
51. 
Another noteworthy finding from our studies in platelets was that pre-treatment with other 
P2Y12R antagonists failed to attenuate adenosine receptor-independent ticagrelor-
stimulated changes in basal VASP-P (Figure 5A-B). This suggests that AR-C 66096, PSB 0739 
and R-138727, reported to bind to or close to the orthosteric/ADP binding site 51-53 did not 
prevent ticagrelor from binding to the P2Y12R. A possible explanation is that ticagrelor binds 
to different residues to where the other antagonists bind. Closer examination of the 
2MeSADP (agonist)-bound state crystal structure of the P2Y12R revealed that ticagrelor 
cannot dock inside the 2MeSADP-binding cavity, whereas ADP and some P2Y12R antagonists, 
including AR-C 66096 do have access51. Ticagrelor’s bulky side chains on N6 have been 
suggested to cause a steric clash, with docking likely requiring P2Y12R helical 
rearrangements5. A study assessing P2Y12R function in CHO cells indicated that ticagrelor 
acted in a competitive manner based on functional readouts although only low 
concentrations of ticagrelor (<30nM) were included in the analysis28. In conflicting studies, 
ticagrelor has been shown to display characteristics of a non-competitive antagonist, 
decreasing the maximum response (Emax) as well as right-shifting the ADP concentration-
response curve4. Ticagrelor did not displace [3H]ADP from the receptor (Ki > 10μM) but 
displaced 2MeS-ADP from membranes prepared from human washed platelets4. However, 
docking analysis would suggest that different binding sites for ADP and 2MeSADP are 
unlikely51. Relating to our platelet studies (Figure 1B) and Schild analysis in cell lines (Figure 
7C), the data indicate that ticagrelor is acting in a non-competitive manner versus ADP. Due 
to the complex pharmacology of ticagrelor, it appears in our studies to behave as a non-
competitive antagonist at a functional level although it may well bind to the 
orthosteric/ADP-binding site.  
12 
 
Only few inverse agonists are documented to act at the P2Y12R
54. Ding et al. (2006) reported 
that AR-C78511 increased cAMP generation in cells expressing a chimeric P2Y12R that 
displayed a high degree of constitutive activity, and is thus a potent inverse agonist 55. A 
follow-up study also revealed that AR-C78511 had superior antiplatelet activity compared to 
a neutral antagonist (cangrelor) in transgenic mice expressing the same chimeric receptor 56. 
Interestingly, AR-C78511, like ticagrelor, could not be docked to the 2MeSADP-bound 
conformation of the P2Y12R, seemingly due to its own bulky N
6 substituents51. 
In summary, ticagrelor has a unique mode of action on human platelets, through blockade 
of agonist-dependent and independent P2Y12R activity and through adenosine uptake 
inhibition. Notably these studies were carried out ex vivo after blood drawing with platelets 
isolated by centrifugation in the presence of anticoagulant with most assays carried out in 
the absence of erythrocytes and plasma. With these limitations of experimental design in 
mind the relative contribution of agonist-dependent and independent P2Y12R activity in vivo 
to the clinical efficacy of ticagrelor remains to be determined.  
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Drug Emax (AU) 
p-value 
relative to 
control 
 p-value 
relative to 
ticagrelor 
n 
Vehicle control 
0.92 [0.88 - 
0.96] 
NA *** 16 
Ticagrelor 
0.41 [0.38 – 
0.45] 
*** NA 22 
AR-C 66096 
0.61 [0.56 – 
0.66] 
*** *** 12 
R-138727 
0.61 [0.57 – 
0.66] 
*** *** 12 
 
Table 1. Maximal responses (Emax) from ADP concentration vs. Ca
2+ peak response curves 
(as calculated in GraphPad Prism) obtained in the presence of different P2Y12R 
antagonists. Responses were recorded from washed platelets after incubation with vehicle 
(0.1% DMSO) or test compound (all at 10 µM; 30 minutes). 95% confidence for Emax values 
are shown in square brackets. *** indicates p <0.001. 
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Figure 1. ADP-induced platelet aggregation and intracellular Ca2+ release  
(A) ADP (10 µM)-induced platelet aggregation in human PRP after 30-minute incubation at 
30 °C with ticagrelor (; IC50 = 0.27μM [0.14 - 0.51]; n=3), AR-C 66096 (; IC50 = 0.16μM [0.08 
– 0.33] n=4) or R-138727 (; IC50 = 3.82μM [3.03 – 4.82]; n=6). 95% confidence intervals for 
IC50s are shown in square brackets. (B) ADP-induced Ca
2+ peak responses in Fura-2 AM-
loaded platelets in the presence of vehicle (; n=16) or 10 µM ticagrelor (; n=22), AR-C 
66096 (; n=12) or R-138727 (; n=12). Baseline readings were recorded over a period of 5 
cycles (each cycle ~ 7 s) before ADP addition, after which recording was continued for a 
further 15 cycles. The peak Ca2+ response was determined by calculating the change in 
fluorescence ratio (340 nm/380 nm). (C) ADP (100µM)-induced platelet peak Ca2+ responses 
in the presence of vehicle (0.1% DMSO), ticagrelor (10µM), ticagrelor (10µM) + XAC (10µM), 
AR-C 66096 (10µM) and R-138727 (10µM). Data displayed as mean and SEM. * indicates 
p<0.05. 
 
Figure 2. Time- and concentration-dependence of increases in platelet VASP-P 
Representative immunoblots and bar/x-y charts showing VASP-P, VASP and α-tubulin 
(internal control) levels in washed platelets after pre-incubation at 37 °C with: (A-B) 10µM 
ticagrelor for 0, 0.5, 5, 10, 15, 30 and 60 minutes; n=5. (C-D) vehicle (0.1% DMSO), 0.1, 0.3, 
1, 3 and 10µM ticagrelor for 60 minutes; n=5. (E-F) untreated, vehicle (0.1% DMSO), 
ticagrelor (10 µM), AR-C 66096 (10µM), PSB 0739 (10 µM) and R-138727 (10µM) for 60 
minutes; n=4. (G-H) untreated, vehicle (0.1% DMSO), ticagrelor (10µM) and NECA (µM) for 
60 minutes following pre-incubation at 37 °C for 30 minutes with: untreated, vehicle (0.1% 
DMSO) or XAC (1µM), n=6. Data displayed as mean and SEM. ** indicates p<0.01; ***, 
p<0.001; and ns, p>0.05. Statistical analysis used was two-way ANOVA (Figure 2H). 
Kilodaltons of molecular size markers are reported on the left. 
 
Figure 3. Role for platelet-expressed ENT1 in the ticagrelor-induced increase in platelet 
VASP-P 
Representative immunoblots and bar charts showing VASP-P, VASP and α-tubulin (internal 
control) levels in washed platelets after incubation at 37 °C with: (A-B) no drug, vehicle 
(0.1% DMSO for 60 min), NBMPR (1 µM for 0.5, 5, 10, 15, 30 and 60 min) or ticagrelor 
(10µM for 0.5, 5, 10, 15, 30 and 60 min); n=5. (C-D) vehicle (0.1% DMSO), ticagrelor (10 µM), 
NBMPR (1µM), ticagrelor (10µM) + NBMPR (1 µM), adenosine deaminase (10 µg/ml), 
adenosine deaminase (10 µg/ml) + ticagrelor (10 µM) and adenosine deaminase + NBMPR (1 
µM); n=3. (E) Immunoblots showing expression of ENT1 in platelets and 1321N1 cells, with 
rat glial cells as negative control. Figure is representative of three replicates. Data displayed 
as mean and SEM. * indicates p<0.05; **, p<0.01; and ns, p>0.05. Statistical test used was 
two-way ANOVA (Figure 3B). Kilodaltons of molecular size markers are reported on the left 
or in the middle for Figure G. 
 
Figure 4. Identification of an adenosine receptor-independent component of the 
ticagrelor-induced increase in platelet VASP-P and cAMP 
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Representative immunoblots and bar/x-y charts showing VASP-P, VASP and α-tubulin 
(loading control) levels in washed platelets after incubation at 37 °C with: (A-B) vehicle 
(0.1% DMSO for 60 minutes) or 10 µM ticagrelor for 0.5, 5, 10, 15, 30 and 60 minutes 
following pre-incubation of all samples (except vehicle control) with XAC (10 µM, at 37 °C) 
for 90 minutes; n=3. (C-D) vehicle (0.1% DMSO), 0.1, 0.3, 1, 3 and 10 µM ticagrelor for 60 
minutes following pre-incubation of all samples (except vehicle control) with XAC (10 µM at 
37 °C) for 90 minutes; n=5. (E-F) no drug, vehicle (0.1% DMSO), ticagrelor (10 µM) and NECA 
(1 µM) for 60 minutes following pre-incubation of all samples (except vehicle control) with 
XAC (10 µM at 37 °C) for 90 minutes; n=5. (G-H) vehicle (0.1% DMSO), ticagrelor (10 µM), 
AR-C 66096 (10 µM), PSB 0739 (10µM) and R-138727 (10µM) for 60 minutes * indicates p < 
0.05; **, p<0.01; ***, p<0.001 and ns, p > 0.05. Kilodaltons of molecular size markers are 
shown on left of blots. 
 
Figure 5. Ticagrelor-mediated, adenosine receptor-independent increases in platelet 
VASP-P in the presence of other P2Y12 antagonists 
(A-B) Representative immunoblots and bar charts showing VASP-P, VASP and α-tubulin 
(internal control) levels in washed platelets after incubation (60 minutes) at 37 °C with 
vehicle (0.1% DMSO), ticagrelor (10µM) or NECA (1µM). Pre-incubation conditions were 
either vehicle (0.1% DMSO) + XAC (10µM), AR-C 66096 (10 µM) + XAC (10 µM), PSB 0739 (10 
µM) + XAC (10µM) or R-138727 (10 µM) + XAC (10 µM), all at 37 °C for 30 minutes; n=7. (C-
D) cAMP accumulation in washed platelets. (C) Platelets were pre-incubated with either 
ticagrelor, AR-C 66096 and R-138727 (all at 10 μM; 60 mins) or vehicle control. Platelets 
were stimulated with PGE1 (1 μM; 10 mins) in the absence or presence of ADP (10 μM) with. 
(D) Effect of antagonists on basal cAMP levels. Incubation (60 minutes) at 37 °C with vehicle 
(0.1% DMSO), ticagrelor (10µM), PSB 0739 (10µM) or R-138727 (10µM) for 60 minutes and 
pre-incubation with XAC (10μM; 60 mins). All bar charts display mean and SEM. Statistical 
test used was two-way ANOVA (excluding NECA data) (Figure 5B). * indicates p<0.05; **, 
p<0.01; and ***, p<0.001. Kilodaltons of molecular size markers are shown on blots. 
 
Figure 6. Ticagrelor-mediated adenosine receptor-independent increases in VASP-P in 
1321N1 cells expressing P2Y12R. 
Representative immunoblots and bar/x-y charts showing: (A-B) VASP-P, VASP and α-tubulin 
(internal control) levels in P2Y12-transfected 1321N1 cells incubated with phosphodiesterase 
inhibitor IBMX (100µM), adenylyl cyclase activator forskolin (100nM), forskolin (100nM) + 
ADP (10µM), ADP (10µM), ticagrelor (10 µM), AR-C 66096 (10 µM) or R-138727 (10µM) for 5 
minutes at 37 °C; n=5. (C-D) ERK-P, ERK and α-tubulin (internal control) levels in P2Y12-
transfected 1321N1 cells incubated with ticagrelor for 0, 5, 10, 15, 30 and 60 minutes, at 37 
°C; n=5 (E-F) VASP-P and α-tubulin (internal control) levels in P2Y12-transfected (E left) and 
vehicle vector pcNEO-transfected (E right) 1321N1 cells, both pre-incubated with either XAC 
(1 µM) or vehicle (0.1% DMSO) for 15 minutes at 37 °C before incubation with ticagrelor (10 
µM) for 0, 5, 15, 30 and 60 minutes at 37 °C. All bar/x-y charts display mean and SEM. 
Statistical test used was two-way ANOVA (Figure 6D). * indicates p<0.05; **, p<0.01 
Kilodaltons of molecular size markers are reported on the left. 
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Figure 7. Ticagrelor-mediated attenuation of agonist-dependent and –independent P2Y12R 
activity in 1321N1 cells. 
Inhibition of forskolin (1 µM; 10 min)-induced cAMP production by ADP (0.1 nM – 100 µM; 
10 min) in P2Y12R-transfected 1321N1 cells after pre-incubation with (A) ticagrelor (3-30 
nM; 15 minutes) or (B) AR-C 66096 (AR-C; 3-30 nM; 15 min); n=5. (C) Schild-plot analysis of 
data from (A) and (B). (D) Forskolin (0.1 nM – 1 µM; 10 min)-induced increases in cAMP 
levels in pcNEO-transfected and P2Y12R-transfected 1321N1 cells. (E) Forskolin (1 µM; 10 
min)-induced cAMP production in pcNEO-transfected and P2Y12-transfected cells incubated 
with vehicle (0.1% DMSO), ticagrelor (10 µM), AR-C 66096 (10 µM) or R-138727 (10 µM) for 
30 minutes. (F) Forskolin (1 µM; 10 min)-induced cAMP after pre-incuabtion with vehicle 
(0.1% DMSO) or ticagrelor (0.01 µM – 10 μM; 30 min) in P2Y12R-transfected cells; n=5. All 
graphs and bar charts display mean ± SEM. All cells were incubated with 0.2 U/ml apyrase 
(37 °C; 60 min) prior to drug additions. * indicates p<0.05 versus pcNEO controls. 
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